Working group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
Working group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
As part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.
As part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.
The digitization of healthcare is paving the way to accelerate drug development in the industry, and the FDA is doing its best to support industry.
As pharmaceutical companies become increasingly focused on retaining key sales people, they continually consider ways to leverage variable compensation as a strategic tool for maximizing the return on their investment in top talent.
Could the new Vermont Drug Transparency law “lead the US Pharmaceutical industry to an awful end”? Tom Norton reports.
The outlook for pharma M&A continues to be strong, writes Michael Jewell.
Regulatory Affairs Professionals Society's Executive Director, Paul Brooks, discusses the looming uncertainty about what will happen after the UK leaves the European Union as many important details remain unclear.
Jean-Francois Denault outlines a systemic approach to evaluating the commercial viability of a product.
Common strategies to overcome bottlenecks and how fast they might lead to results are discussed.
Executives from DIA, Ranjini Prithviraj and Sudip Parikh discuss documents the FDA released that further detail the agency’s implementation plan for its Software Precertification Pilot Program.
Executives from DIA, Ranjini Prithviraj and Sudip Parikh discuss documents the FDA released that further detail the agency’s implementation plan for its Software Precertification Pilot Program.
Advice for developers in steering gene therapies from concept to trials to hopeful approval in what is an uniquely complex path.
Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.
Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.
Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.
Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.
Jianan Huang outlines the market prospects for first-line treatments for liver cancer treatment in China.
Thinning talent pools, combined with evolving industry trends and job-seeker motivations, are testing traditional pharma hiring methods, where targeting new skills and capabilities must become the new norm.
Thinning talent pools, combined with evolving industry trends and job-seeker motivations, are testing traditional pharma hiring methods, where targeting new skills and capabilities must become the new norm.
Nine ways pharma companies can maximize a CDO’s potential value and impact on driving innovation as a business mandate.
Nine ways pharma companies can maximize a CDO’s potential value and impact on driving innovation as a business mandate.
The cell and gene therapy space remains fertile territory for growth, exploration, and discovery. How applying a data-driven model may be the best way to approach this complex ecosystem and assess the innovations of tomorrow.
Teams and organizations that rely solely on the HR function for succession planning are doing themselves a disservice, write Joy Taylor and Kim Lehman.
The significant scale that is necessary to break into the healthcare marketplace poses the greatest barrier to entry for women entrepreneurs. Shaleta Dunn outlines strategies that aspiring businesswomen can adopt to foster their success.
Outdated processes and technologies make it difficult for organizations to customize materials without going through repetitive review cycles. Jason Sundberg outlines how two companies addressed these challenges with a combination of modern cloud technology, disciplined process design, and careful change management.
Gary Lyon explores the role and impact of three elements of marketing planning that drive business success: Segmentation, Targeting, and Positioning.
As manufacturers look to commercialize new medicines, it is important to evaluate partners that can provide a fully integrated offering aligned to product performance goals and offer a seamless customer experience.